As more states expand adult Medicaid dental benefits, participation remains low and GOP-backed federal cuts threaten to reverse recent progress, raising concerns for physicians and dentists.
The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.